vs
TOMPKINS FINANCIAL CORP（TMP）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
TOMPKINS FINANCIAL CORP的季度营收约是再鼎医药的1.5倍（$194.8M vs $127.1M），TOMPKINS FINANCIAL CORP同比增速更快（152.7% vs 17.1%），TOMPKINS FINANCIAL CORP自由现金流更多（$31.9M vs $-26.7M），过去两年TOMPKINS FINANCIAL CORP的营收复合增速更高（63.6% vs 20.8%）
汤普金斯金融公司是一家小型多元化金融服务企业，总部位于纽约州伊萨卡，是汤普金斯信托银行及其他多家银行、一家保险代理机构和财富管理部门的母公司。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TMP vs ZLAB — 直观对比
营收规模更大
TMP
是对方的1.5倍
$127.1M
营收增速更快
TMP
高出135.5%
17.1%
自由现金流更多
TMP
多$58.6M
$-26.7M
两年增速更快
TMP
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $127.1M |
| 净利润 | $96.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 71.7% | -54.6% |
| 净利率 | 49.4% | — |
| 营收同比 | 152.7% | 17.1% |
| 净利润同比 | 388.9% | — |
| 每股收益（稀释后） | $6.72 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TMPZLAB
| Q4 25 | $194.8M | $127.1M | ||
| Q3 25 | $87.4M | $115.4M | ||
| Q2 25 | $82.6M | $109.1M | ||
| Q1 25 | $81.7M | $105.7M | ||
| Q4 24 | $77.1M | $108.5M | ||
| Q3 24 | $76.6M | $101.8M | ||
| Q2 24 | $72.7M | $100.1M | ||
| Q1 24 | $72.8M | $87.1M |
净利润TMPZLAB
| Q4 25 | $96.2M | — | ||
| Q3 25 | $23.7M | $-36.0M | ||
| Q2 25 | $21.5M | $-40.7M | ||
| Q1 25 | $19.7M | $-48.4M | ||
| Q4 24 | $19.7M | — | ||
| Q3 24 | $18.6M | $-41.7M | ||
| Q2 24 | $15.7M | $-80.3M | ||
| Q1 24 | $16.9M | $-53.5M |
毛利率TMPZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率TMPZLAB
| Q4 25 | 71.7% | -54.6% | ||
| Q3 25 | 35.6% | -42.3% | ||
| Q2 25 | 34.2% | -50.3% | ||
| Q1 25 | 31.6% | -53.3% | ||
| Q4 24 | 33.4% | -62.6% | ||
| Q3 24 | 32.0% | -66.6% | ||
| Q2 24 | 28.3% | -76.0% | ||
| Q1 24 | 30.4% | -80.7% |
净利率TMPZLAB
| Q4 25 | 49.4% | — | ||
| Q3 25 | 27.1% | -31.2% | ||
| Q2 25 | 26.0% | -37.3% | ||
| Q1 25 | 24.1% | -45.8% | ||
| Q4 24 | 25.5% | — | ||
| Q3 24 | 24.3% | -40.9% | ||
| Q2 24 | 21.6% | -80.2% | ||
| Q1 24 | 23.2% | -61.4% |
每股收益（稀释后）TMPZLAB
| Q4 25 | $6.72 | $-0.05 | ||
| Q3 25 | $1.65 | $-0.03 | ||
| Q2 25 | $1.50 | $-0.04 | ||
| Q1 25 | $1.37 | $-0.04 | ||
| Q4 24 | $1.39 | $-0.09 | ||
| Q3 24 | $1.30 | $-0.04 | ||
| Q2 24 | $1.10 | $-0.08 | ||
| Q1 24 | $1.18 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $132.8M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $938.4M | $715.5M |
| 总资产 | $8.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TMPZLAB
| Q4 25 | $132.8M | $689.6M | ||
| Q3 25 | $193.5M | $717.2M | ||
| Q2 25 | $212.6M | $732.2M | ||
| Q1 25 | $193.1M | $757.3M | ||
| Q4 24 | $134.4M | $779.7M | ||
| Q3 24 | $132.3M | $616.1M | ||
| Q2 24 | $70.9M | $630.0M | ||
| Q1 24 | $57.1M | $650.8M |
股东权益TMPZLAB
| Q4 25 | $938.4M | $715.5M | ||
| Q3 25 | $788.8M | $759.9M | ||
| Q2 25 | $761.8M | $791.7M | ||
| Q1 25 | $741.4M | $810.8M | ||
| Q4 24 | $713.4M | $840.9M | ||
| Q3 24 | $719.9M | $667.7M | ||
| Q2 24 | $674.6M | $704.2M | ||
| Q1 24 | $667.9M | $762.2M |
总资产TMPZLAB
| Q4 25 | $8.7B | $1.2B | ||
| Q3 25 | $8.5B | $1.2B | ||
| Q2 25 | $8.4B | $1.2B | ||
| Q1 25 | $8.2B | $1.2B | ||
| Q4 24 | $8.1B | $1.2B | ||
| Q3 24 | $8.0B | $985.3M | ||
| Q2 24 | $7.9B | $987.4M | ||
| Q1 24 | $7.8B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $31.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 16.4% | -21.0% |
| 资本支出强度资本支出/营收 | 3.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.40× | — |
| 过去12个月自由现金流最近4个季度 | $105.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TMPZLAB
| Q4 25 | $38.9M | $-26.0M | ||
| Q3 25 | $34.9M | $-32.0M | ||
| Q2 25 | $18.9M | $-31.0M | ||
| Q1 25 | $22.2M | $-61.7M | ||
| Q4 24 | $95.0M | $-55.8M | ||
| Q3 24 | $21.2M | $-26.8M | ||
| Q2 24 | $27.3M | $-42.2M | ||
| Q1 24 | $23.2M | $-90.1M |
自由现金流TMPZLAB
| Q4 25 | $31.9M | $-26.7M | ||
| Q3 25 | $33.9M | $-35.0M | ||
| Q2 25 | $18.3M | $-33.9M | ||
| Q1 25 | $20.9M | $-63.2M | ||
| Q4 24 | $88.8M | $-58.4M | ||
| Q3 24 | $18.9M | $-28.2M | ||
| Q2 24 | $26.3M | $-42.9M | ||
| Q1 24 | $21.9M | $-91.1M |
自由现金流率TMPZLAB
| Q4 25 | 16.4% | -21.0% | ||
| Q3 25 | 38.8% | -30.4% | ||
| Q2 25 | 22.1% | -31.1% | ||
| Q1 25 | 25.5% | -59.9% | ||
| Q4 24 | 115.1% | -53.8% | ||
| Q3 24 | 24.7% | -27.7% | ||
| Q2 24 | 36.2% | -42.9% | ||
| Q1 24 | 30.0% | -104.5% |
资本支出强度TMPZLAB
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 1.7% | 1.5% | ||
| Q4 24 | 8.1% | 2.4% | ||
| Q3 24 | 2.9% | 1.3% | ||
| Q2 24 | 1.3% | 0.7% | ||
| Q1 24 | 1.9% | 1.1% |
现金转化率TMPZLAB
| Q4 25 | 0.40× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 1.13× | — | ||
| Q4 24 | 4.82× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.74× | — | ||
| Q1 24 | 1.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TMP
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
